 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- || leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella, AXA1125 / Axcella
Clinical, Journal: Safety, Tolerability, and Biologic Activity of AXA1125 and AXA1957 in Subjects With Nonalcoholic Fatty Liver Disease. (Pubmed Central) - Feb 22, 2022
Both compositions showed multitargeted activity on relevant NAFLD pathways. AXA1125 demonstrated the greatest activity over 16 weeks, warranting continued clinical investigation in nonalcoholic steatohepatitis subjects.
- leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella
Enrollment change, Trial termination, Trial primary completion date: Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Sep 7, 2020
P=N/A, N=9, Terminated, Sponsor: Axcella Health, Inc
AXA1125 demonstrated the greatest activity over 16 weeks, warranting continued clinical investigation in nonalcoholic steatohepatitis subjects. N=30 --> 9 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Apr 2020; Sponsor has determined that information it would have collected would not inform future development of a therapy with AXA 1957 for NAFLD
- ||| leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella, AXA1125 / Axcella
Trial completion: Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Sep 3, 2020
P=N/A, N=102, Completed, Sponsor: Axcella Health, Inc
N=30 --> 9 | Recruiting --> Terminated | Trial primary completion date: Aug 2020 --> Apr 2020; Sponsor has determined that information it would have collected would not inform future development of a therapy with AXA 1957 for NAFLD Active, not recruiting --> Completed
- | leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella, AXA1125 / Axcella
Trial completion date: Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Jul 7, 2020
P=N/A, N=105, Active, not recruiting, Sponsor: Axcella Health, Inc
Active, not recruiting --> Completed Trial completion date: Mar 2020 --> Sep 2020
- | leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella, AXA1125 / Axcella
Enrollment closed: Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Oct 9, 2019
P=N/A, N=105, Active, not recruiting, Sponsor: Axcella Health, Inc
Trial completion date: Mar 2020 --> Sep 2020 Recruiting --> Active, not recruiting
- | leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella, AXA1125 / Axcella
New trial: Study of the Safety and Tolerability of AXA1125 and AXA1957 in Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Aug 29, 2019
P=N/A, N=105, Recruiting, Sponsor: Axcella Health, Inc
- | leucine/isoleucine/arginine/glutamine/N-acetylcysteine/carnitine/serine (AXA1957) / Axcella
New trial: Study of the Safety and Tolerability of AXA1957 in Adolescent Subjects With Non-Alcoholic Fatty Liver Disease (NAFLD) (clinicaltrials.gov) - Aug 29, 2019
P=N/A, N=30, Recruiting, Sponsor: Axcella Health, Inc